<DOC>
	<DOCNO>NCT01377363</DOCNO>
	<brief_summary>This Prospective Clinical Trial without drug , determine HER2 status metastasis patient primary breast cancer HER2 . 236 patient recruit 32 Sites take part Clinical Trial . Primary Objective : - To determine prospectively probability stage HER2 conversion different subtypes primary breast cancer ( luminal , triple negative HER2 ) metastasis . Secondary Objective : - To determine probability change ER PR different subtypes primary breast cancer metastasis . - Analyze variability measurement HER2 , ER PR local laboratory central laboratory . - Evaluate HER2 conversion rate compare previously receive treatment . - Evaluate whether location metastasis biopsied relates probability conversion HER2 . - Compare disease-free survival ( DFS ) survival post relapse ( SPR ) patient without conversion HER2 ER/PR . - Compare response rate ( RR ) time progression ( TTP ) subsequent anti-tumor treatment patient without conversion HER2 . - Analyze extent discrepancy HER2 receptor status , ER PR primary tumor metastasis alter clinical management patient . - Analyze feasibility perform biopsy . - Evaluate whether HER2 status conversion really associate activation intracellular marker HER2 signal pathway : pMAPK , PERK , pAKT , PTEN , PIGF-1R pair sample ( primary tumor metastasis ) . - Check change molecular subtypes ( luminal , triple negative , HER2 ) primary tumor metastases patient HER2 conversion .</brief_summary>
	<brief_title>Evaluation Degree Conversion HER2 Receptor Between Primary Breast Cancer Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients give write informed consent participate study . Women 18 year . Breast cancer locally recurrent metastatic first relapse successive progression . Patient available sample primary tumor paraffin . Patients plan next 6 week , biopsy ( fine needle aspiration / drainage fluid cavity , open biopsy , core biopsy ) locally recurrent metastatic lesion [ local relapse chest wall , nodal , cutaneous subcutaneous metastasis , peripheral lymph node soft tissue accessible , bone metastasis , visceral metastasis ( lung , liver , brain , etc.. ) pleural effusion / ascites / pericardial / cerebrospinal ] accord clinical practice center . Patients cognitive impairment might impede proper understand write informed consent , accord medical criterion . ipsilateral breast local relapse contralateral breast away . Patients diagnosed second neoplasm , exception cervical carcinoma situ nonmelanoma skin carcinoma treat properly .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>primary breast cancer</keyword>
</DOC>